NIA

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Retrieved on: 
水曜日, 5月 15, 2024
Probability, Insurance, Patient, NIA, Basal forebrain, CRVO, DLB, MD, Operating cost, Research, Research and development, G&A, Administration, Pharmaceutical industry

BOSTON, May 15, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported its financial results for the first quarter ended March 31, 2024.

Key Points: 
  • BOSTON, May 15, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported its financial results for the first quarter ended March 31, 2024.
  • We remain on track to complete enrollment in the RewinD-LB trial during the second quarter of this year, followed by topline efficacy results expected in the fourth quarter of 2024.
  • On April 1, 2024, CervoMed completed a private placement of up to $149.4 million joined by leading healthcare investors.
  • General and Administrative (G&A) Expenses: G&A expenses were approximately $2.1 million during the first quarter of 2024 versus approximately $1.0 million in the first quarter of 2023.

Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update

Retrieved on: 
火曜日, 5月 7, 2024
Lewy body, SHIMMER, DLB, Research, Cognition, Public expenditure, SHINE, Therapy, NIA, Pharmaceutical industry

PURCHASE, N.Y., May 07, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • PURCHASE, N.Y., May 07, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the first quarter ended March 31, 2024, and provided a business update.
  • The Company estimates that it has sufficient cash to fund operations and capital expenditures through the second quarter of 2025.
  • Research and development expenses were $10.6 million for the quarter ended March 31, 2024, compared to $5.4 million for the comparable period in 2023.
  • General and administrative expenses were $3.5 million for the quarter ended March 31, 2024, compared to $3.5 million for the comparable period in 2023.

Philippines Construction Equipment Rental Market Assessment & Forecasts 2024-2029: Flood Mitigation and Adaptation Projects, Infrastructure Flagship Projects Fueling Demand - ResearchAndMarkets.com

Retrieved on: 
月曜日, 4月 29, 2024
Construction & Property, Other Construction & Property, Carbon, Nature, Mineral, Volvo, PIP, Cyclone, Cat, Disaster, Komatsu, MGB, DENR, Hitachi Construction Machinery, Monark Equipment Corporation, Environment, United States Geological Survey, TRIP, NIA, National Irrigation Administration, Department of transportation, Iron, XCMG, Department of Transportation (Philippines), MMDA, Government, JCB, Mine, Workforce, Landslide, NZCA, Kobe Steel, Earthquake, Terex, Public works, Research, Artificial intelligence, NEDA, Caterpillar, CNH Industrial, PAR, Manitou, USD, Lead, Construction, Flood, Automation, Internet of things, SANY, Cobalt, CCA, Natural Resources, DPWH, Nickel

The Philippines construction equipment rental market was estimated at 175.9 million in 2023 and is expected to grow at a CAGR of 5.06% from 2023-2029.

Key Points: 
  • The Philippines construction equipment rental market was estimated at 175.9 million in 2023 and is expected to grow at a CAGR of 5.06% from 2023-2029.
  • Caterpillar, Komatsu, Volvo CE, Hitachi Construction Machinery, XCMG, and SANY are leaders in the Philippines construction equipment rental market.
  • JCB, Kubota, Kobelco, Zoom Lion, and Sumitomo Construction Machinery are emerging in the Philippines construction equipment rental market.
  • This effort targets improving national and communal irrigation systems to boost farmer productivity and profitability while driving demand for earthmoving machinery rentals in government-led projects in the Philippines construction equipment rental market.

Scotia Wealth Management teams up with Gordie Howe CARES to support Canadian caregivers and their families

Retrieved on: 
火曜日, 4月 23, 2024
Education, Alzheimer's disease, Health, Conference, Research, Friends, Senior, Family, Principal, Caregiver, Ageing, Longevity, NIA, CIA, Residential care

Scotia Wealth Management's sponsorship of Gordie Howe CARES will enable further research, education and support to caregivers who are dedicating their time caring for loved ones.

Key Points: 
  • Scotia Wealth Management's sponsorship of Gordie Howe CARES will enable further research, education and support to caregivers who are dedicating their time caring for loved ones.
  • Gordie Howe CARES provides caregivers of people living with Alzheimer's and dementia-related diseases with support and education.
  • "As the caregiving landscape changes and gets more challenging, the type of support provided to Gordie Howe CARES by Scotia Wealth Management is very welcome.
  • Learn more about Gordie Howe CARES and their mission to support and understand the challenges faced by caregivers, health care professionals and family and friends.

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
月曜日, 4月 1, 2024
Lewy body, Research, GBA, Administration, Plasma, Conference, MRI, DLB, GFAP, Basal forebrain, Patient, Journal, Chairperson, Sale, TID, Manuscript, Public expenditure, Biomarker, Glial fibrillary acidic protein, MD, University College London, Atrophy, Publication, Frontotemporal dementia, Alpha-synuclein, NIA, Research and development, Vertex Pharmaceuticals, Axonal transport, Dementia, CRVO

BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported its financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Moreover, the neflamapimod treatment effects on GFAP were correlated to clinical outcomes, assessed by the CDR-SB.
  • Cash Position: As of December 31, 2023, CervoMed had $7.8 million in cash and cash equivalents as compared to $4.1 million as of December 31, 2022.
  • This increase was attributed to the RewinD-LB Phase 2b clinical study in DLB which began in the first quarter of 2023.
  • Net Loss: Net Loss was $2.2 million for the year ended December 31, 2023, compared to a net loss of $5.8 million for year ended December 31, 2022.

Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update

Retrieved on: 
火曜日, 3月 26, 2024
Research, Corporation, Conference, DLB, Alzheimer's disease, Disease, Biomarker, Public expenditure, Translational Neurodegeneration, Completeness, Vance DeGeneres, Protein, Clinical trial, Quantitative electroencephalography, Therapy, NIA, SHIMMER, Cognition, Pharmaceutical industry

PURCHASE, N.Y., March 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update. Management will host a live webcast conference call at 8:00am ET to review 2023 accomplishments. Details of the call are provided below.

Key Points: 
  • ET -
    PURCHASE, N.Y., March 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
  • Cognition scientists published two manuscripts and made 11 presentations at medical and scientific congresses in 2023, advancing the understanding of its foundational science and clinical implications.
  • “We achieved a number of critical clinical objectives in 2023,” said Lisa Ricciardi, Cognition’s president and CEO .
  • Management will host a conference call and live webcast to discuss Cognition’s financial results today at 8:00 a.m.

Thought Leaders, Entrepreneurs and Active Investors Come Together to Shape Innovation at the 21st Annual What's Next Longevity Venture Summit

Retrieved on: 
火曜日, 4月 9, 2024
Dark, Fairmont San Francisco, Head, Conference, MFA, Longevity, AARP, Government, Learning, Growth, Incubator, Running, AI, Investment banking, Ziegler, Housing, Summit, NIA, National Institute on Aging

LAFAYETTE, Calif., April 9, 2024 /PRNewswire/ -- Mary Furlong & Associates (MFA), producer of the longest running conference on the longevity economy, announced that the What's Next Longevity Venture Summit, will bring together thought leaders, including active investors, entrepreneurs, incubators, nonprofits, government agencies, providers and companies focused on the $9.5 trillion longevity market, June 11-12 at the Fairmont San Francisco. The theme, Net New: Investment, AI & Innovation In the Longevity Marketplace, will drive discussions on the key challenges and opportunities for those supporting the age 50+ market.

Key Points: 
  • The theme, Net New: Investment, AI & Innovation In the Longevity Marketplace, will drive discussions on the key challenges and opportunities for those supporting the age 50+ market.
  • "We put a laser focus on the active investors in the space today, highlighting the investment opportunities as well as forming partnerships for success in longevity.
  • And, to demonstrate their continued commitment to the Summit, the AgeTech Collaborative from AARP will be the title sponsor of this year's conference."
  • The What's Next Longevity Venture Summit will take place at the Fairmont San Francisco, June 11-12.

Congress Passes Bills Making Major Investments in Alzheimer’s

Retrieved on: 
土曜日, 3月 23, 2024
Congress, Medical imaging, Caregiver, Health equity, DSM-IV codes, Research, National Institute on Aging, National coverage determination, Investment, CDC, NINDS, Language, Dementia, NIA, Medicare, NCD, CMS, Pharmaceutical industry

WASHINGTON, March 23, 2024 (GLOBE NEWSWIRE) -- As part of a budget bill heading to President Biden for his signature, Congress passed major investments in the fight against Alzheimer’s; specifically demonstrating its unwavering commitment to equity and inclusion in the reporting language, which helps to foster a more equitable and just healthcare system.

Key Points: 
  • WASHINGTON, March 23, 2024 (GLOBE NEWSWIRE) -- As part of a budget bill heading to President Biden for his signature, Congress passed major investments in the fight against Alzheimer’s; specifically demonstrating its unwavering commitment to equity and inclusion in the reporting language, which helps to foster a more equitable and just healthcare system.
  • “We are thrilled to witness Congress’s steadfast 12-year commitment to Alzheimer’s research, despite ongoing budget restraints,” said UsAgainstAlzheimer’s chair and co-founder George Vradenburg.
  • UsAgainstAlzheimer’s worked to include language encouraging diversity in clinical trials, and the establishment of a brain health equity initiative to improve the integration of brain health into primary care, particularly within underrepresented communities.
  • The bill also encourages the National Institute of Biomedical Imaging and Bioengineering to collaborate with National Institute of Aging (NIA) and The National Institute of Neurological Disorders and Stroke (NINDS) to develop new technologies that could discover the earliest biological events that lead to Alzheimer’s disease and related dementias.

The University of Texas Health Science Center at San Antonio announces the passing of William L. Henrich, MD, president since 2009

Retrieved on: 
金曜日, 3月 15, 2024
Alzheimer's disease, Barshop Institute, Biomedical Research, Health, Patient, History, Quality of life, Humour, University, MACP, Love, NIA, Pandemic, Dementia, Ageing, NCI, Obesity, Innovation, UT System, Diabetes, SAN, NIH, Workforce, Transplant, Intelligence, Public, FACP, Integration, News, Textbook, Cancer, Dialysis, Haematopoietic system, Family, Neurodegenerative disease, Dentistry, Growth, COVID-19, School, Life, University of Texas System, MARC, Nursing

SAN ANTONIO, Texas, March 14, 2024 /PRNewswire-PRWeb/ -- It is with profound sadness that The University of Texas of Health Science Center at San Antonio (UT Health San Antonio) announces that William L. Henrich, MD, MACP, president of UT Health San Antonio, passed away this morning, March 14, 2024. There will be announcements about Dr. Henrich's memorial services soon.

Key Points: 
  • SAN ANTONIO, Texas, March 14, 2024 /PRNewswire-PRWeb/ -- It is with profound sadness that The University of Texas of Health Science Center at San Antonio (UT Health San Antonio) announces that William L. Henrich, MD, MACP, president of UT Health San Antonio, passed away this morning, March 14, 2024.
  • Dr. Henrich was able to return as president in February 2013 and presided over the unprecedented growth experienced by UT Health San Antonio.
  • The University of Texas Health Science Center at San Antonio (UT Health San Antonio), a primary driver of San Antonio's $44.1 billion health care and biosciences sector, is the largest academic research institution in South Texas with an annual research portfolio of $413 million.
  • Monica Taylor, The University of Texas Health Science Center at San Antonio, 210-450-8970, [email protected] , https://news.uthscsa.edu/

Gravitrex Wins National Institute on Aging Startup Challenge

Retrieved on: 
金曜日, 2月 23, 2024
Bangladesh Technical Education Board, Burns, Entrepreneurship, NIH, Quality of life, NIA, Hospital, Health, Startup company, Mentorship, Disability, Walking, Death, BWS, Disease, Research

PHOENIX, Feb. 23, 2024 /PRNewswire-PRWeb/ -- Gravitrex, a rehabilitation technology startup, today announced that it won the National Institute on Aging (NIA) Startup Challenge to advance commercialization of its radically new walking-assist device, that will increase access to walking rehabilitation for older adults after hospitalization or a fall. This prestigious award validates the potential of Gravitrex's innovative technology to significantly impact health outcomes for older adults.

Key Points: 
  • PHOENIX, Feb. 23, 2024 /PRNewswire-PRWeb/ -- Gravitrex , a rehabilitation technology startup, today announced that it won the National Institute on Aging (NIA) Startup Challenge to advance commercialization of its radically new walking-assist device, that will increase access to walking rehabilitation for older adults after hospitalization or a fall.
  • -Kira Burns, Co-founder & CEO
    NIA is a division of The National Institutes of Health (NIH) and the Startup challenge supports products aimed at improving the health and quality of life for older adults in minority and underserved populations.
  • Burns added, "We would like to extend our deepest gratitude to the National Institute on Aging for this award, and for the significant investment in resources committed during the entire Startup Challenge Program.
  • We are confident that NIA's investment in the Startup Challenge will lead to the commercialization of multiple technologies that will positively impact health outcomes for older adults in underserved populations."